title: Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type.
abstract: The objective of the current study was to assess the prognostic factors in patients with extranodal natural killer (NK)/T cell lymphoma, nasal type (ENKL). We retrospectively analyzed 35 patients who were diagnosed with ENKL between 1998 and 2011. The median patient age was 63 years, and the male/female ratio was 22:13; twenty patients had localized ENKL, and 26 had a good Eastern Cooperative Oncology Group performance status (score 0 or 1). B symptoms were present in 17 patients. Twenty-five patients presented with nasal or paranasal lesions, or both. With a median follow-up duration among patients still alive at their last follow-up of 47 months (range 8-93 months), the 3-year overall survival (OS) rate was 44.5 %. Multivariate analysis revealed that advanced disease stage (P = 0.002), the presence of extranasal disease (P = 0.013), and serum ferritin levels greater than 300 ng/ml (P < 0.001) were significant and independent (negative) prognostic factors. High serum ferritin levels were associated with the presence of B symptoms, elevated lactate dehydrogenase levels, and high soluble interleukin-2 receptor levels, but not with clinical stage. Patients with high ferritin levels had a remarkably low remission rate (23 %) and a short OS time (median: 4 months). Serum ferritin level at the time of diagnosis of ENKL was a useful prognostic factor.
authors.affiliation: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura Kanazawa-ku, Yokohama, 2360004, Japan, etsukoy@yokohama-cu.ac.jp.
authors.forename: Etsuko
authors.initials: E
authors.lastname: Yamazaki
authors.forename: Naoto
authors.initials: N
authors.lastname: Tomita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Koyama
authors.forename: Eriko
authors.initials: E
authors.lastname: Ogusa
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Ishii
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Kazuho
authors.initials: K
authors.lastname: Miyashita
authors.forename: Shiro
authors.initials: S
authors.lastname: Matsuura
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Tachibana
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Takasaki
authors.forename: Sachiya
authors.initials: S
authors.lastname: Takemura
authors.forename: Katsumichi
authors.initials: K
authors.lastname: Fujimaki
authors.forename: Rika
authors.initials: R
authors.lastname: Sakai
authors.forename: Shin
authors.initials: S
authors.lastname: Fujisawa
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishigatsubo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005293:Ferritins / Q000097:blood*; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000097:blood* / Q000453:epidemiology / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000097:blood* / Q000453:epidemiology / Q000401:mortality*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D005293:Ferritins
references.citation: Eur J Haematol. 2012 Aug;89(2):103-10
references.pmid: 22553935
references.citation: Cancer. 1998 Aug 15;83(4):806-12
references.pmid: 9708949
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5594-600
references.pmid: 19805668
references.citation: Int J Hematol. 2003 Jul;78(1):18-23
references.pmid: 12894846
references.citation: Ann Oncol. 2010 May;21(5):1032-40
references.pmid: 19850638
references.citation: J Clin Oncol. 1999 Apr;17(4):1244
references.pmid: 10561185
references.citation: Am J Hematol. 1980;9(1):13-22
references.pmid: 7001894
references.citation: Ann Oncol. 2004 Jul;15(7):1091-6
references.pmid: 15205204
references.citation: Proc Natl Acad Sci U S A. 1981 Jul;78(7):4515-9
references.pmid: 6270680
references.citation: J Clin Oncol. 1992 Feb;10(2):219-27
references.pmid: 1370690
references.citation: J Clin Oncol. 1999 Aug;17(8):2461-70
references.pmid: 10561310
references.citation: Blood. 1996 Feb 15;87(4):1207-10
references.pmid: 8608206
references.citation: Pathol Int. 2000 Sep;50(9):696-702
references.pmid: 11012982
references.citation: Med Oncol. 2012 Sep;29(3):2176-82
references.pmid: 21710236
references.citation: Blood. 2009 Apr 23;113(17):3931-7
references.pmid: 19029440
references.citation: Blood. 2004 Jan 1;103(1):216-21
references.pmid: 12933580
references.citation: J Clin Oncol. 2011 Nov 20;29(33):4410-6
references.pmid: 21990393
references.citation: Hematol Oncol. 2008 Jun;26(2):66-72
references.pmid: 18283711
references.citation: Ann Oncol. 2006 May;17(5):794-800
references.pmid: 16497823
references.citation: Am J Clin Oncol. 1990;13 Suppl 1:S15-9
references.pmid: 2291455
references.citation: J Clin Oncol. 2006 Feb 1;24(4):612-8
references.pmid: 16380410
references.citation: Leuk Lymphoma. 2014 Feb;55(2):270-5
references.pmid: 23647063
references.citation: Ann Oncol. 2005 Feb;16(2):206-14
references.pmid: 15668271